Health state utility values in major depressive disorder treated with pharmacological interventions: a systematic literature review

Brockbank, James; Krause, Taryn; Moss, Emily; Pedersen, Anne Milthers; Mørup, Michael Frank; Ahdesmäki, Outi; Vaughan, Jake; Brodtkorb, Thor-Henrik

doi:10.1186/s12955-021-01723-x

Table 2 Summary of health state utility values from included studies

From: Health state utility values in major depressive disorder treated with pharmacological interventions: a systematic literature review

Author, Country	Health state	Clinical stratification	MDE	Prior therapy	Intervention	Utility estimate (SD)^a	Instrument
Asia
Lee et al. [14], multinational	MDD	PPS +	New or first episode	NR	Starting new ADT	0.37 (0.01)	EQ-5D-3L^b
Lee et al. [14], multinational	MDD	PPS −	New or first episode	NR	Starting new ADT	0.61 (0.02)	EQ-5D-3L^b
Ang et al. [11], multinational	MDD	Overall	New or first episode	NR	Starting an SSRI	0.497 (0.1945)	EQ-VAS
Ang et al. [11], multinational	MDD	Overall	New or first episode	NR	Starting an SNRI	0.437 (0.2076)	EQ-VAS
Lee et al. [13], Korea	MDD	PPS +	New or first episode	NR	Starting new ADT	0.2 (0.36)	EQ-5D-3L^b (UK tariff; Korean population has not been validated)
Lee et al. [13], Korea	MDD	PPS −	New or first episode	NR	Starting new ADT	0.5 (0.30)
Chen et al. [12], Taiwan	MDD	Overall	New or first episode	NR	Starting new ADT	0.481 (0.1978)	EQ-VAS
					Starting an SSRI	0.488 (0.2017)
					Starting an SNRI	0.463 (0.1874)
		PPS +			Starting new ADT	0.429 (0.1826)
		PPS −			Starting new ADT	0.598 (0.1821)
Li et al. [15], China	MDD	Overall	New or first episode	NR	Starting an SNRI	0.4553 (0.2364)	EQ-VAS
					Starting an SSRI	0.4717 (0.1897)
					Starting new ADT	0.4581 (0.2057)
		PPS +				0.3848 (0.2238)
		PPS −				0.4957 (0.1854)
Novick et al. [17], multinational	MDD	Adherent	New or first episode	NR	Starting new ADT	0.46 (0.34)	EQ-5D-3L^b (UK tariff)
		Nonadherent				0.37 (0.36)	EQ-5D-3L^b (UK tariff)
		Adherent				0.4536 (0.1962)	EQ-VAS
		Nonadherent				0.4884 (0.2010)	EQ-VAS
Novick et al. [16], China	MDD	Overall	New or first episode	NR	Starting new ADT	0.52 (0.31)	EQ-5D-3L^b (UK tariff)
Novick et al. [16], China	MDD	Overall	New or first episode	NR	Starting new ADT	0.455 (0.209)	EQ-VAS
Kuga et al. [19], Japan	MDD	PPS +	NR	No ADT for at least 4 weeks	Starting duloxetine	0.5055 (0.1504)	EQ-5D^c
Kuga et al. [19], Japan	MDD	PPS +	NR	No ADT for at least 4 weeks	Starting an SSRI	0.5016 (0.1602)	EQ-5D^c
Kim et al. [20], South Korea	MDD	Overall	New or first episode (59.6% were newly diagnosed)	22.8% had received prior ADT	Receiving ADT	0.726 (0.192)	EQ-5D^c
	Very severe MDD	MADRS 35–60				0.615 (0.209)
	Severe MDD	MADRS 30–34				0.718 (0.186)
	Moderate MDD	MADRS 26–29				0.746 (0.145)
	Remission or mild MDD	MADRS 0–25				0.806 (0.166)
Husain et al. [21], Pakistan	Treatment-resistant MDD	Overall	Current episode ≥ 4 weeks	Current episode has failed to remit with ≥ 2 ADTs (including current ADT received for ≥ 4 weeks)	Starting placebo (with current ADT)	0.44 (0.191)	EQ-VAS
Husain et al. [21], Pakistan	Treatment-resistant MDD	Overall	Current episode ≥ 4 weeks		Starting minocycline (with current ADT)	0.424 (0.167)	EQ-VAS
Europe
Montgomery et al. [22], multinational	MDD	Overall	Single or recurrent episode < 12 months duration	Inadequate response to ADT for ≥ 6 weeks prior to study screening	Starting agomelatine	0.468 (0.194)	EQ-VAS
Montgomery et al. [22], multinational	MDD	Overall	Single or recurrent episode < 12 months duration		Starting vortioxetine	0.455 (0.183)	EQ-VAS
Papakostas et al. [23], multinational	MDD with nonresponse or partial response to 1 ADT	Overall	Single or recurrent episode; current episode < 12 months duration	Inadequate response to SSRI ≥ 6 weeks prior to study screening	Starting agomelatine	0.470 (0.198)	EQ-VAS
					Starting vortioxetine	0.449 (0.185)
				Inadequate response to SNRI ≥ 6 weeks prior to study screening	Starting agomelatine	0.464 (0.185)
					Starting vortioxetine	0.470 (0.176)
Garcia-Cebrian et al. [24], and Reed et al. [25], multinational	MDD	Overall	New or first episode	NR	Starting new ADT	0.44 (0.31)	EQ-5D-3L^b
Kuyken et al. [27], UK	Recurrent MDD in full or partial remission	Overall	3 or more previous episodes	Included patients who “were on a therapeutic dose of ADM in line with the British National Formulary (BNF) 48 and NICE guidance”	Starting m-ADT	0.778 (0.211)	EQ-5D-3L
Kuyken et al. [27], UK	Recurrent MDD in full or partial remission	Overall	3 or more previous episodes		Starting MBCT-TS	0.760 (0.268)	EQ-5D-3L
Serfaty et al. [29], UK	MDD	Overall	77% of the total population had previous episode of depression	If taking an ADT, on a stable dose for at least 8 weeks prior to the study	ADT	0.46 (0.29)	EQ-5D
					ADT + CBT	0.50 (0.32)
					ADT + TC	0.52 (0.31)
Morriss et al. [28], UK	MDD	Overall	Current episode	Offered or received direct and continuous care in the preceding 6 months	Starting TAU	0.337 (0.343)	EQ-5D-3L
Morriss et al. [28], UK	MDD	Overall	Current episode		Starting SDS	0.361 (0.329)	EQ-5D-3L
Sapin et al. [30], France	MDD	Overall	New episode	No prior ADT	Starting ADT	0.33 (0.25)	EQ-5D-3L^b
	Responders remitters	MADRS ≤ 12			Received ADT for 8 weeks	0.85 (0.13)
	Responders nonremitter	MADRS decrease > 50%				0.72 (0.20)
	Nonresponders	MADRS decrease < 50%				0.58 (0.28)
Fernandez et al. [26], multinational	MDD	Overall	New episode	No prior ADT	Starting escitalopram	0.52 (0.3)	EQ-5D-3L^b (UK tariff)
Fernandez et al. [26], multinational	MDD	Overall	New episode	No prior ADT	Starting venlafaxine	0.54 (0.3)	EQ-5D-3L^b (UK tariff)
Saragoussi et al. [31], multinational	MDD	Overall	Current episode	21.3% switching ADT and 78.7% no prior ADT	Starting new ADT	0.5 (0.3)	EQ-5D-3L^b (UK tariff)
The Americas
Revicki and Wood [33], Canada and US	MDD	Overall	Current episode	Receiving current ADT or had completed an ADT regimen within the last 2 months prior to the study	Receiving ADT	0.74 (0.22)	Standard gamble (patients)
	Severe MDD				Untreated	0.30 (0.28)
	Moderate MDD				Nefazodone	0.63 (0.23)
					Fluoxetine	0.63 (0.19)
					Imipramine	0.55 (0.03)
	Mild MDD				Nefazodone	0.73 (0.21)
					Fluoxetine	0.70 (0.20)
					Imipramine	0.64 (0.20)
	Remission (maintenance treatment)				Nefazodone	0.83 (0.13)
					Fluoxetine	0.80 (0.15)
					Imipramine	0.72 (0.17)
	Remission (off treatment)				Untreated	0.86 (0.16)
Multiregional
Hong et al. [37], multinational	MDD	Overall	Current episode	Initiating or switching ADT with up to 1 previous inadequate response to ADT; no ADT received 1 week prior to study	Starting duloxetine	0.46 (0.32)	EQ-5D-3L^b (UK tariff)
		Overall			Starting an SSRI	0.47 (0.33)
		PPS +			Starting duloxetine	0.37 (0.33)
		PPS +			Starting an SSRI	0.40 (0.34)
		PPS −			Starting duloxetine	0.58 (0.26)
		PPS −			Starting an SSRI	0.54 (0.31)
		Overall			Starting duloxetine	0.4339 (0.2436)	EQ-VAS
		Overall			Starting an SSRI	0.4299 (0.2694)
		PPS +			Starting duloxetine	0.4077 (0.2423)
		PPS +			Starting an SSRI	0.3948 (0.2725)
		PPS −			Starting duloxetine	0.4707 (0.2411)
		PPS −			Starting an SSRI	0.4602 (0.2636)

ADM Antidepressant Medication, ADT Antidepressant Treatment, CBT Cognitive-Behavioral Therapy, EQ-5D-3L 3-Level EQ-5D, EQ-VAS EQ Visual Analogue Scale, MADRS Montgomery-Åsberg Depression Rating Scale, MBCT-TS Mindfulness-Based Cognitive Therapy with Support to Taper, MDD Major Depressive Disorder, MDE Major Depressive Episode, NICE National Institute for Health and Care Excellence, NR Not Reported, PPS Painful Physical Symptoms, SD Standard Deviation, SDS Specialist Depression Services, SNRI Serotonin-Norepinephrine Reuptake Inhibitor, SSRI Selective Serotonin Reuptake Inhibitor, TAU Treatment As Usual, TC Talking Control, UK United Kingdom, US United States
^aEQ-VAS scores were converted from a 0–100 scale to a 0–1 scale
^bEQ-5D-3L was not explicitly stated in the study, but was deduced, either from the date of the study or from the date of references to EQ-5D methodology (the EQ-5D-5L was introduced after 2009)
^cThe use of EQ-5D-3L or EQ-5D-5L was not stated, nor could it be deduced based on the date of the study or references

Back to article page

ISSN: 1477-7525

Contact us

Submission enquiries: journalsubmissions@springernature.com

Health and Quality of Life Outcomes

Contact us